IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.491
NA - Nord America 5.030
AS - Asia 875
AF - Africa 72
SA - Sud America 28
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 6
Totale 13.517
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.989
IT - Italia 2.197
IE - Irlanda 1.493
GB - Regno Unito 1.267
RU - Federazione Russa 650
SE - Svezia 620
SG - Singapore 327
DE - Germania 325
FR - Francia 301
FI - Finlandia 247
CN - Cina 240
UA - Ucraina 104
ES - Italia 90
IN - India 86
VN - Vietnam 66
CZ - Repubblica Ceca 59
CI - Costa d'Avorio 55
CA - Canada 35
NL - Olanda 35
IR - Iran 28
HK - Hong Kong 20
BE - Belgio 16
AU - Australia 14
CH - Svizzera 14
PH - Filippine 14
TR - Turchia 14
PL - Polonia 10
AT - Austria 9
JP - Giappone 9
BR - Brasile 8
PT - Portogallo 8
BG - Bulgaria 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
AZ - Azerbaigian 6
CL - Cile 6
EU - Europa 6
PE - Perù 6
BD - Bangladesh 5
DK - Danimarca 5
KZ - Kazakistan 5
LK - Sri Lanka 5
LT - Lituania 5
LV - Lettonia 5
MA - Marocco 5
EE - Estonia 4
EG - Egitto 4
GE - Georgia 4
HR - Croazia 4
KG - Kirghizistan 4
KR - Corea 4
MK - Macedonia 4
NG - Nigeria 4
AR - Argentina 3
CY - Cipro 3
EC - Ecuador 3
LA - Repubblica Popolare Democratica del Laos 3
RO - Romania 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AM - Armenia 2
CO - Colombia 2
GR - Grecia 2
HU - Ungheria 2
ID - Indonesia 2
IL - Israele 2
JO - Giordania 2
MX - Messico 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
TW - Taiwan 2
CR - Costa Rica 1
DZ - Algeria 1
JM - Giamaica 1
MD - Moldavia 1
MM - Myanmar 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SI - Slovenia 1
TH - Thailandia 1
Totale 13.517
Salva come PNG Salva come JPEG
Città #
Dublin 1.466
Southend 1.187
Chandler 623
Fairfield 617
Santa Clara 552
Siena 466
Ashburn 406
Lastra a Signa 340
Singapore 262
Woodbridge 230
Wilmington 224
Helsinki 216
Houston 212
Seattle 202
Princeton 186
Cambridge 179
New York 137
Ann Arbor 126
Florence 126
Milan 93
Munich 84
Shanghai 71
Rome 67
Dong Ket 64
Jacksonville 64
Fremont 63
Beijing 62
Moscow 59
Málaga 59
San Mateo 59
Abidjan 55
San Diego 50
Dearborn 47
Boardman 45
Los Angeles 42
Brno 40
Dallas 27
Washington 27
London 26
Gavirate 24
Chicago 21
Agliana 19
Lappeenranta 19
Nuremberg 18
Tarazona 17
Brussels 16
Livorno 16
Padova 16
Naples 15
Olomouc 15
Toronto 15
Hyderabad 13
Brescia 12
Hong Kong 12
Nanjing 12
Zanjan 12
Aachen 11
Cagliari 11
Newark 11
Chianciano Terme 10
Comun Nuovo 10
Pasig 10
Pune 10
Redwood City 10
Amsterdam 9
Bangalore 9
Espoo 9
Guangzhou 9
Norwalk 9
Pisa 9
San Francisco 9
Vienna 9
Zurich 9
Bergamo 8
Grosseto 8
Izmir 8
Nanchang 8
Paris 8
Prato 8
Carrara 7
Leawood 7
Salerno 7
San Casciano in Val di Pesa 7
Sofia 7
Anagni 6
Baku 6
Catania 6
Delhi 6
Falkenstein 6
Frankfurt am Main 6
Hefei 6
Kilburn 6
Lima 6
Rubano 6
Turin 6
Verona 6
Winnipeg 6
Bari 5
Bologna 5
Catanzaro 5
Totale 9.473
Salva come PNG Salva come JPEG
Nome #
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 203
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 203
Genetic mechanisms of critical illness in COVID-19 203
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 198
Peripheral biomarkers' panel for severe COVID-19 patients 196
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 193
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 188
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 177
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 169
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 169
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 166
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 166
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 161
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 156
NK and NKT-like cells in granulomatous and fibrotic lung diseases 155
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 155
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 149
Prognostic bioindicators in severe COVID-19 patients 143
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 142
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 142
Serum amyloid A in patients with idiopathic pulmonary fibrosis 140
Pathogen-sugar interactions revealed by universal saturation transfer analysis 135
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 135
Mapping the human genetic architecture of COVID-19 134
Serial KL-6 measurements in COVID-19 patients 128
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 126
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 124
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 124
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 123
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 121
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 121
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 120
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 120
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 119
A first update on mapping the human genetic architecture of COVID-19 118
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 118
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 117
Serum amyloid A: A potential biomarker of lung disorders 116
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 115
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 115
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 112
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 112
null 111
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 110
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 110
An explainable model of host genetic interactions linked to COVID-19 severity 108
Effects of rituximab therapy on B cell differentiation and depletion 106
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 105
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 104
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 104
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 104
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 103
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 102
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 102
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 100
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 100
WES profiling of COVID-19 100
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 99
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 99
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 98
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 98
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 98
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 98
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 96
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 96
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 95
Immunologic responses to antifibrotic treatment in IPF patients 95
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 93
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 91
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 90
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 90
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 89
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 89
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 89
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 88
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 86
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 84
Clinical and molecular characterization of COVID-19 hospitalized patients 83
Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report 83
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 81
Clinical phenotyping in sarcoidosis management 81
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 80
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 80
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 80
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 79
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis 77
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 77
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 76
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 76
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 75
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 73
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 73
Serum Amyloid A in lung transplantation 72
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 72
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 71
The Role of Galectins in Chronic Lung Allograft Dysfunction 70
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 69
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 68
Serial autoantibody detection in interstitial lung diseases: should they be repeated at follow-up? 68
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach 68
Totale 11.289
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.691
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.691
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020612 0 0 0 0 0 83 85 103 101 98 51 91
2020/20212.166 64 100 101 271 185 246 160 256 217 147 217 202
2021/20222.306 175 268 201 159 113 100 95 104 101 295 262 433
2022/20232.707 175 294 334 266 155 479 283 236 183 117 111 74
2023/20243.095 119 95 316 163 158 661 869 147 43 103 119 302
2024/20252.886 603 268 757 395 788 75 0 0 0 0 0 0
Totale 14.221